What happened
On August 28, 2026, the FDA approved Mimrylo (rusfertide) for adults with polycythemia vera and granted the approval to Takeda Pharmaceuticals America, Inc. The agency described Mimrylo as the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that regulates iron in the body. The goal is to limit iron available to make new red blood cells and reduce overproduction.
The approval was based on the phase 3 VERIFY trial, a multicenter, randomized, double-blind, placebo-controlled study of 293 adults with polycythemia vera who required frequent phlebotomies despite ongoing standard-of-care therapy. Patients were randomized 1:1 to Mimrylo or placebo over 32 weeks. Mimrylo started at 19 mg subcutaneously once weekly and was titrated to maintain hematocrit below 45%.
The primary efficacy measure was the proportion of patients who did not meet criteria for phlebotomy between weeks 20 and 32. In the study, 76.9% of patients on Mimrylo required no phlebotomies during the 32-week period, versus 32.9% on placebo. The most common adverse reactions were injection site reactions and anemia. Mimrylo also received priority review.
Why it matters
This approval matters because the FDA framed the burden in very practical terms: many patients still need frequent blood draws, and keeping hematocrit below 45% is a key treatment goal to reduce cardiovascular risks. Mimrylo’s label positioning, at least from the FDA release, is not broad disease control in the abstract. It is specifically about adults whose disease has not been adequately controlled with existing therapies, particularly those still requiring frequent phlebotomy.
That should shape early uptake, payer review, and physician use. For detailed drug monographs, see ClinicalRx.ai.
Our read is that first-in-class status will get attention. Access discussions are likely to center on where exactly the product sits relative to existing therapies and how tightly plans define inadequate control and frequent phlebotomy. The trial result is clinically clean on the endpoint the FDA highlighted, but investors and payers will now watch how Takeda translates phlebotomy reduction into real-world use and persistence, especially given weekly subcutaneous administration and the adverse reactions the FDA listed. For broader drug pricing context, see RxInfo.ai.
